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ABSTRACT 
This paper is a case study on how pharmaceuticals are prescribed on the NHS in the UK. The 
paper discusses the modelling and forecasting of pharmaceutical life cycles, specifically 
around after the time of patent expiry. In this situation one of two things can occur the 
branded pharmaceutical sales remain high while the generic are low, the alternative is when 
the branded drug declines and stays low while the sales of the generic drug are high.. 
Understanding the patterns of brand decline (and the associated generic growth) is 
increasingly important because in a market currently worth over £7bn in the UK, the number 
of new ‘blockbuster’ drugs continues to decline. As a result pharmaceutical companies make 
efforts to extend the commercial life of their brands, and the ability to forecast is important in 
this regard.  Second, this paper provides insights for effective governance because the use of 
a branded drug (when a generic is available) results in wasted resources. Five methods are 
used to model and forecast these life cycles: Bass Diffusion, Repeat Purchase Diffusion 
Model (RPDM), Naïve, Exponential Smoothing and Moving Averages. The empirical 
evidence presented here suggests that the use of the Naïve model incorporating drift provided 
the most accurate and robust method of modelling both types of prescribing, with the more 
advanced models being less accurate.  
 
Keywords: Forecasting; Diffusion Models; Pharmaceutical Lifecycles; Branded drugs; 
Generic drugs. 
 
INTRODUCTION 
 
Over the past three decades, marketers have been encouraged from both within and outside 
the Marketing profession to become more socially relevant by broadening their viewpoints 
and extending their research into areas not traditionally associated with marketing (Churchill, 
1999). Andreasen (1978) has reported that marketing professionals and academics alike 
should strive to become more socially aware. Secondly, Armstrong, Brodie, and McIntyre 
(1987) found that forecasting was included in more than 98% of companies’ marketing plans 
and argued that forecasting should be taught in business schools. Despite the importance of 
forecasting, managers do not appear to use the technique effectively. Khan’s (2002) survey of 
marketing managers found self-reported forecast accuracy of just 47% for new category 
entrants, and only 40% for products that were new to the world.   
 
This paper describes an approach for forecasting pharmaceutical life cycles. The model 
specifically focuses on the life cycle of branded and generic drugs in which the sales of 
branded drugs decline and prescriptions for generic alternatives increase or vice versa. In this 
arena, successful forecasting enables marketing managers to implement strategies that allow 
them to advantageously modify a product’s life, and we therefore demonstrate an application 
of practical use to managers.  
 
Wind, Mahajan, and Cardozo (1981)  reviewed the many models used to predict new product 
sales, but they were limited to consumer goods and did not address pharmaceuticals. Lilien, 
Rao, and Kalish (1981) proposed a model that specifically considers pharmaceutical drugs. 
Rao and Yamada (1988) made a number of changes to this model and tested its predictability 
again using pharmaceutical data. Rao and Yamada (1988) posited that like other methods 
used to predict consumer goods, the traditional Bass (1969) model cannot be applied to 
pharmaceutical products. The application and predictability of diffusion models have 
received limited empirical testing with mixed results; however, as shown by Nikolopoulos et 
al (2007) complicated forecasting techniques do not always generate the most accurate 
results, and in some situations, simpler approaches can be more effective. The OR forecasting 
paradigm allows competition between different techniques to determine the best solution. 
Nikolopoulos et al. (2007) used this approach in the marketing field and Bamiatzi, Bozos, 
and Nikolopoulos (2010) conducted research using financial data. In this study, the OR 
forecasting paradigm is applied to the pharmaceutical industry, highlighting the changing 
nature of prescription drugs when generic alternatives enter a market previously dominated 
by branded versions of the same drug. 
 
The study contributes to the existing body of literature by applying forecasting methods to the 
life cycles of pharmaceutical drugs. Previous studies by Cox (1967) and Easingwood (1987) 
modelled pharmaceutical life cycles but did not incorporate the forecasting element. This 
research aims to update and extend the existing literature by applying forecasting techniques 
to the data, with a specific focus on the life cycles of branded drugs that decline as soon as 
generic alternatives enter the marketplace.  
 
This research models and forecasts pharmaceutical life cycles using the Bass Diffusion model 
(1969), the Repeat Purchase Diffusion Model proposed by Lilien et al. (1981) and the 
adaptations proposed by Rao and Yamada (1988), and benchmark models including the 
Moving Average, Exponential Smoothing, and Naïve Models. As this is a working paper, the 
results gathered will be available at the conference.  
 
MATHEMATICAL MODELS 
 
Diffusion Model literature 
Mahajan, Muller, and Bass (1990) demonstrate that Diffusion Models have been employed in 
several areas of marketing, including consumer behaviour, marketing management and 
marketing science research. In the field of marketing science, researchers have contributed to 
the diffusion theory by developing forecasting techniques associated with Diffusion Models.   
 
Bass Diffusion Model 
Diffusion Models were initially developed by Frank Bass (1969). The Bass Diffusion Model 
describes how new products are adopted as an interaction between users and potential users. 
This theory of adoption and diffusion was first developed conceptually by Rogers (1962.  
 
Individuals can decide to adopt a product independently of other influences. These people are 
generally known as the innovators of a product. Bass (1969) highlights five classes of 
adopters: (1) Innovators; (2) Early Adopters; (3) Early Majority; (4) Late Majority and (5) 
Laggards. Rogers (1962) describes groups (2) through to (5) as imitators. Imitators make 
decisions based on information gained from other individuals in the same social group, such 
as friends or family. Rogers (1962) describes innovators as daring and notes that they have a 
tendency to interact with other innovators. These consumers are not influenced by the timing 
of purchases made by other members of their social group, and their pressure to adopt a 
product does not increase as the number of people adopting the product grows. The pressure 
of adoption is only felt by consumers in groups (2) through group (5), not by group (1) 
(Rogers, 1962).  
The two main assumptions of the Bass Diffusion Model (1969) are as follows: 
a) During the life of a product, there will be m initial purchases of that product. When 
replacement purchases are made, sales combine both the replacement and the initial 
purchases leading to the second assumption, which provides the main equation for the 
Bass Diffusion Model.  
b) The likelihood of an initial purchase at time T, given that no purchase has yet been 
made, is as follows: 
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Therefore, sales S(t) is the rate of change of the installed base (i.e., the rate of adoption) f(t) 
multiplied by the ultimate market potential m: 
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The time of peak sales t* is 
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In these equations, f(t) is the rate of change based on the initial base fraction. F(t) is the 
installed base fraction; p is the coefficient of innovation, including the coefficients of 
innovation, advertising effects and external influences; and q is the coefficient of imitation, 
including the coefficient of imitation, word-of-mouth effects, and internal influences (Bass, 
1969).  
 
The behavioural justifications behind these two assumptions are outlined here: 
I. Initial purchases of any product are generally made by both imitators and innovators. 
The underlying distinction between the innovator and the imitator is how the 
purchaser comes to be influenced to purchase the product. Innovators are not 
influenced by the number of people in their social groups that have purchased the 
product, while imitators are. Innovators have greater importance when the product is 
first launched, but this importance decreases steadily over time.  
II. For successful new products, the coefficient of imitators is generally greater than the 
coefficient of innovators. Sales reach their maximum value when the total sales are 
approximately one-half of m. When t is measured in years, the typical values of p and 
q are as follows: 
a. On average, p is 0.03; more often than not, it is 0.01. 
b. On average, q is 0.38; more often than not, it falls between 0.3-0.5. This also 
demonstrates that on average, the coefficient of imitators is greater than the 
coefficient of innovators.  
 
The regression analysis and model performance must then be analysed, allowing long-range 
forecasts to be produced. The model developed by Bass (1969) implies exponential growth 
followed by a peak and then a decline. The model provides good predictions for the products 
to which it was applied and, according to Bass, it is useful in providing a basic rationale for 
long-range forecasting (Bass, 1969).  
 
The Bass Model has been influential in both marketing and management science, and the 
1969 paper is one of the most frequently cited in the management science literature. There 
have also been many extensions of the original Bass Diffusion Model; the model used in this 
paper is Lilien et al’s. (1981) Repeat Purchase Diffusion Model, which has also been used to 
model the sales of ethical drugs.  
 
Repeat Purchase Diffusion Model (RPDM) 
Lilien et al. (1981) proposed a three-step methodology to predict the sales of new drugs when 
they enter the market when little or no prior data are available. The steps Lilien et al. (1981) 
propose are as follows: 
 
1. To use historical time series data associated with prescription drug introductions to 
develop sales models as a function of the total number of GPs in the target market and 
a number of other marketing variables. Because GPs have a tendency to repeat-
prescribe new drugs, the model represents a repeat purchase diffusion process.  
2. A model is then produced to forecast the sales of the new drug prior to entering the 
market. Lilien et al. (1981) have suggested that this model is parameterised on a drug 
that the management deem “similar” to the new drug being introduced to the market.  
3. The final step aims to use early sales data gathered to update the model to make it 
more accurate using Bayesian regression. As Rao and Yamada (1988) note, this 
approach is valid when no prior data are available, but if sales data are available, the 
RPDM can be used accurately to produce one-step-ahead forecasts.  
 
The Lilien et al. (1981) model is based on the assumption that a linear relationship exists 
between the number of prescribers and the number of prescriptions written. The model can be 
operationalised as follows: 
  
 (5)
  
Y (t)=Y (t -1)+ f (t)[a1d(t -1)-a2d
2(t -1)] ×[N -Y (t -1)]+a3[Y (t -1)-Y (t -2)]×
[N -Y (t -1)]- a4d(t -1)Y (t -1)
            
  
Where 
 
Y(t) is the number of prescriptions written at time t; 
 d(t) is the firm’s detailing effort at time t; 
  ̅( ) is the competitive detailing effort at time t; 
f(t) is the decay rate: i.e., early prescribers tend to prescribe the most and f(t) will decline as t 
increases; 
N is the total potential number of prescribers multiplied by the average prescription rate;  
Ai i = 1,…4 are constants. 
 
Rao and Yamada (1988) show how the Lilien et al (1981) model could be updated when new 
sales data for the drugs being researched become available, and given the research objectives 
and the data available, their model was deemed appropriate. The Rao and Yamada (1988) 
model is as follows: 
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Rao and Yamada (1988) found that the Lilien et al. (1981) model provides the best fit for 
pharmaceutical data when the decay factor is removed. For this reason, in the Rao and 
Yamada (1988) version, f(t) is set to 1. In addition, in the Rao and Yamada (1988) version, 
the parameters N and a1, a2, a3, a4 are unknown; u(t) is included as a disturbance term. It is 
assumed that the disturbances are all independently and normally distributed with a zero 
mean and a common variance. Consistent with the OR paradigm, a number of other basic 
benchmark models are also used, including the Naïve Model, Exponential Smoothing and 
Moving Average techniques.  
 
 
 
THE DATA 
The time series associated with the current research are taken from a much larger database 
that contains 2,570,000 prescription records from 1,506 GPs all over the United Kingdom. 
The time series run from 1987-2008. As pharmaceuticals can be prescribed in two forms 
branded and generic, it allows the research to use three different data sets. They are branded 
then generic, high branded and low generic and high generic and low branded.  
The branded then generic category is where the branded drug is prescribed first then due to 
generic entry declines while there is an increased number of prescriptions written for then 
generic drug. Table 1 show the data used in this sample. 
 
 
 
 
 
TABLE 1 
Basic Information of the Branded then Generic Prescription Sample 
 
 
The high branded and low generic data set refers to the pharmaceuticals that are no longer 
protected by a patent and both the branded and generic drug can be prescribed at the same 
time and the number of branded prescriptions written is higher than the number of generic 
prescriptions written. Table 2 shows the data used in this sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Branded 
Drug Generic Drug
Therapeutic 
Class CAS Number 
Patent 
Number Patentee
Year of 
Patent 
Granted
Year of 
Patent 
Expiration
Supplementary 
Protection 
Certificate 
(SPC)
Total Number of 
Prescriptions 
(Rx) between 
1987 and 2008 Sources 
Cardura Doxazosin Hypertension 74191-85-8 US4188390 Pfizer 1980 2000 NA 17990
Merck Index, 
Espacenet
Defanac Diclofenac
Anti-
inflammatory 13307-86-5 GB 1132318 Geigy 1968 1983 NA 167190
Espacenet, Patent 
Archives
Gamanil Lofepramine Anti-depressant 23047-25-8 GB 1177525 Leo 1970 1984 NA 17767
Espacenet, Patent 
Archives
Innovace Enalapril
Angiotensin 
Converting 
Enzyme (ACE) 7475847-73-3 EP12401 Merck and Co 1983 1995 NA 16410 Espacenet 
Losec Omeprazole Acid Reflux 73590-58-6 EP5129 Haessle AB 1979 1999 2005 47751
USPTO, Espacenet, 
MPA services
Lustral Sertraline Anti-depressant 79617-96-2 EP 30081 Pfizer 1981 2000 2005 13201
MPA Services, 
Espacenet
Mobic Meloxicam
Analgesic/Anti-
inflammatory 71125-38-7 EP0002482
Boehringer 
Ingelheim 1979 1998 2003 13276
MPA Services, 
Boehringer Ingelheim, 
Espacenet 
Naprosyn Naproxen
Anti-
inflammatory 22204-53-1 GB 1291386 Syntex 1972 1988 NA 65817
MPA Services, 
Espacenet
Prothiaden Dosulepin** Anti-depressant 113-53-1 GB 1013574 Spofa 1965 1978 NA 45982
Espacenet, MPA 
Sernices
Prozac Fluoxetine Anti-depressant 54910-89-3 GB1493961 Lilly and Co 1977 1995 2000 42813
Espacenet, MPA 
services, Patent 
Archives
Serevent Salmeterol Asthma 89365-50-4 GB2176476 Glaxo 1987 2004 NA 10995
Merck Index, 
Espacenet
Seroxat Paroxetine Anti-depressant 61869-08-7 GB1422263 Ferrosan 1976 1994 1999 30448
Espacenet, MPA 
services, Patent 
Archives
Tagamet Cimetidine Acid reflux 51481-61-9 GB1338169
SmithKline & 
French 1971 1992 NA 41033
Espacenet, Patent 
Archives, Derwent 
Index, MPA Services
Tenormin Atenolol Hypertension 29122-68-7 GB 1285038 ICI 1972 1990 NA 54297
MPA Services, 
Espacenet, Patent 
Archives
Tritace Ramipril Hypertension 87333-19-5 EP79022 Hoechst AG 1983 2002 2004 27898
USPTO, Espacenet, 
MPA services
Zantac Ranitidine
Peptic Ulcer 
Disease 66357-35-5 GB 1565966
Allen & 
Hanburys 1980 1997 NA 46673
MPA Services, 
Espacenet, Patent 
Archives
Zestril Lisinopril
Angiotensin 
Converting 
Enzyme (ACE) 83915-83-7 EP12401 Merck & Co 1980 1999 2002 30642
Merck Index, 
Espacenet, MPA 
Services
Zocor Simvastatin
Controls 
Hyperlipidemia 79902-63-9 EP33538 Merck and Co 1981 2001 NA 34216
Espacenet, MPA 
services
Zoton Lansoprazole
Proton Pump 
Inhibitor 103577-45-3 EP174726
Nippon 
Chemipar 1986
2001(non-
payment of 
fees) NA 37264 USPTO, Espacenet 
TABLE 2 
Basic Information of the High Branded and Low Generic Prescription Sample 
 
 
Finally, the high generic low branded data set refers to pharmaceuticals that are also no 
longer patent protected and this is where the number of generic drug prescriptions is higher 
than the number of branded drug prescriptions. The basic information for this data set can be 
seen in Table 3.  
 
TABLE 3 
Basic Information of the High Generic and Low Branded Prescription Sample 
 
 
 
 
Branded 
Drug Generic Drug
Therapeutic 
Class CAS Number Patent Number Patentee
Year of 
Patent 
Granted
Year of 
Patent 
Expiration
Supplementary 
Protection 
Certificate 
(SPC)
Total Number of 
Prescriptions 
(Rx) between 
1987 and 2008 Sources 
Adalat Nifedipine Hypertension 21829-25-4 GB1173862
Farbenfabriken 
Bayer AG 1969 1988 NA 26905
Espacenet, Merck Index, 
MPA services, Patent 
Archive
Becotide Beclomethasone Asthma 08/09/5534 GB912378 Merck and co 1962 1982 NA 43184 Patent Archives, Espacenet
Feldene Piroxicam
Anti-
inflammatory 36322-90-4 GB1257180 Pfizer 1971 1989 NA 30313
Espacenet, 
patent.ipexl.com/GB/GB12
57180.html
54-31-9 GB936417 (fru) Hoechst AG 1963 1983
2016-88-8 GB1066855 (am) Merck and co 1967 1987
GNT
Glyceryl 
trinitrate Angina 55-63-0 NA NA Pre 1900 NA NA 23520
Walter Sneader, Drug 
Discovery: A History. John 
Wiley & Sons (2005)
Maalox
Aluminium 
hydroxide Acid Reflux 21645-51-2 NA NA NA NA NA 17916 Patent Archives
Maxolon Metoclopramide
Anti-emtic/ 
gastroprokine
tic 
(Nausea/Vomi
ting) 364-62-5 GB 994023 Ile de France 1965 1978 NA 13126 Patent Archives, Espacenet 
Oruvail Ketoprofen
Anti-
inflammatory 22071-15-4 GB1164585
Rhone Poulec 
SA 1969 1989 NA 13963 Patent Archives, Espacenet
82115-62-6 US2565115 Squibb & Son 1951 Expired NA
57-83-0 US2379832 Schering Corp 1945 Expired NA
Ponstan Mefenamic acid
Anti-
inflammatory 67861-88-7 GB989951
Parke Davis 
and Co 1965 1985 NA 17017 Espacenet, Patent Archives
Traxam Felbinac 
Anti-
inflammatory 5728-52-9 FR798941
IG 
Farbenindustrie 
AG 1936 Expired NA 14881 Merck Index, Espacenet
Tryptizol Amitriptyline Anti-depressant 50-48-6 GB858187 Hoffman and La Roche 1961 Expired NA 24354 Patent Archives, Espacenet
Ventolin Salbutamol Asthma 18559-94-9 GB1200886
Allen & 
Hanbury's 1970 1987 NA 54961 Espacenet, Merck Index
Espacenet, Patent Archives
Prempak
Oestrogens + 
Progesterone 
(Norgestrel)
Hormone 
Replacement 
Therapy 51598 Merck Index, Espacenet
Frumil
Furosemide/ 
Amiloride HCL 
(co-amilofruse)
Water 
Retention 13889NA
Branded 
Drug Generic Drug
Therapeutic 
Class CAS Number 
Patent 
Number Patentee
Year of 
Patent 
Granted
Year of 
Patent 
Expiration
Supplementary 
Protection 
Certificate 
(SPC)
Total Number of 
Prescriptions (Rx) 
between 1987 and 
2008 Sources 
Aprinox Bendroflumethiazide Hypertension 78-48-3 GB 863474
F. Lund and W. O. 
Godtfredsen 1961 Expired NA 42441
Patent Archives, 
Espacenet
Brufen Ibuprofen
Anti-
inflammatory 15687-27-1 GB971700 Boots Pure Drug Co 1961 Expired NA 203300
Patent Archives, 
Espacenet
Deltastab Prednisolone
Anti-
inflammatory 50-24-8 US2837464 Schering Corp 1958 Expired NA 29144
Espacenet, Patent 
Archives
DHC Dihydrocodeine
Severe Pain 
Relief 125-28-0 NA NA
Introduced 
1911 NA NA 13592 Merck Index
Flexin Indocid
Analgesic/Anti-
inflammatory 53-86-1 GB 997638 Merck and Co 1965 1978 NA 21409
Patent Archives, 
Espacenet
Inderal Propranolol Hypertension 525-66-6 GB 994918 ICI      1965 1979 NA 11778
Espacenet, Patent 
Archives
Lasix Furosemide
Loop Diuretic 
– water 
retention 54-31-9 GB936417 Hoechst AG 1963 1983 NA 22037
Espacenet, Patent 
Archives
Panadol Paracetamol Analgesic 103-90-2 US2998450 Warner Lambert 1961 Expired NA 24722
Merck Index, 
Espacenet
Zydol Tramadol Analgesic 27203-92-5 GB997399
Chem Gruenenthal 
GMBH 1964 1984 NA 14306
Patent Archives, 
Espacenet
RESULTS 
As this is a working paper the results will be provided during the conference.  
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